Article
Pathology
Gwyneth S. T. Soon, Saba Yasir, Tsung-Teh Wu, Christopher Welle, Sudhakar K. Venkatesh, Michael S. Torbenson, Zongming Eric Chen
Summary: Newer radiotherapy techniques, such as stereotactic body radiation, are increasingly used in the treatment of cholangiocarcinomas, particularly as a bridge to liver transplantation. However, these high-dose therapies result in tissue injury in the peritumoral liver tissue. This retrospective study characterized the morphologic changes in the liver after stereotactic body radiation and found that the changes in the radiated areas were more extensive than in the background liver.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2023)
Review
Gastroenterology & Hepatology
Xing Chen, Jinpeng Du, Jiwei Huang, Yong Zeng, Kefei Yuan
Summary: Intrahepatic cholangiocarcinoma (ICC) is a common type of primary liver cancer with increasing incidence. Due to the lack of specific manifestations and tools for early diagnosis, most patients are diagnosed at an advanced stage. Neoadjuvant and adjuvant therapies are necessary to improve the outcomes, but lag behind compared to other malignancies. Recent advances in neoadjuvant and adjuvant strategies for ICC are evaluated in this review.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2022)
Article
Surgery
Frederik J. H. Hoogwater, Hendrien Kuipers, Vincent E. de Meijer, Charlotte Maulat, Fabrice Muscari, Wojciech G. Polak, Bart van Hoek, Caroline Jezequel, Ian P. J. Alwayn, Jan N. M. Ijzermans, Kayvan Mohkam, Jean-Yves Mabrut, Frederike G. Van Vilsteren, Jean-Philippe Adam, Laurence Chiche, Alexandre Chebaro, Emmanuel Boleslawski, Jeroen Dubbeld, Sarwa Darwish Murad, Michel Rayar, Robert J. Porte
Summary: This study compared outcomes after liver transplantation for perihilar cholangiocarcinoma using strict selection criteria, with or without neoadjuvant chemoradiotherapy. The results showed that patients who received neoadjuvant chemoradiotherapy had lower post-transplant survival rates but lower tumor recurrence rates. Adjustments in neoadjuvant chemoradiotherapy may improve outcomes in these patients. Rating: 7 out of 10.
Review
Gastroenterology & Hepatology
Aditya Borakati, Farid Froghi, Ricky H. Bhogal, Vasileios K. Mavroeidis
Summary: Cholangiocarcinoma is an aggressive malignancy arising from the biliary epithelium, with poor prognosis. Radical surgical resection offers a chance of cure but is often not possible. Orthotopic liver transplantation (LT) allows for a potentially curative resection, but its use has been controversial. However, recent studies have shown favourable results, indicating that the role of LT may increase in the future.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Jan Bednarsch, Zoltan Czigany, Lara R. Heij, Dong Liu, Marcel den Dulk, Georg Wiltberger, Philipp Bruners, Tom Florian Ulmer, Ulf Peter Neumann, Sven Arke Lang
Summary: For patients with iCCA, preoperative radiological characteristics play a crucial role in predicting survival and recurrence-free survival. Patients with a single iCCA <= 3 cm demonstrate better overall survival and recurrence-free survival outcomes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Maen Abdelrahim, Abdullah Esmail, Jiaqiong Xu, Godsfavour Umoru, Hadeel Al-Rawi, Ashish Saharia, Ala Abudayyeh, David Victor, Robert McMillan, Sudha Kodali, Rafik M. Ghobrial
Summary: This study investigates the potential efficacy of Gemcitabine plus Cisplatin as a neo-adjuvant treatment for cholangiocarcinoma patients prior to liver transplantation. The results suggest improved overall survival outcomes with Gemcitabine plus Cisplatin compared to non-Gemcitabine/Cisplatin regimens in these patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Laura Schwenk, Oliver Rohland, Aladdin Ali-Deeb, Felix Dondorf, Utz Settmacher, Falk Rauchfuss
Summary: Liver transplantation can be a possible curative therapy option for patients with combined hepatocellular carcinoma and sole intrahepatic cholangiocarcinoma. Our retrospective study found high overall survival and low recurrence rates in patients after liver transplantation for incidental intrahepatic cholangiocarcinoma or combined tumors. This suggests that liver transplantation could benefit patients with these types of liver cancer.
Review
Gastroenterology & Hepatology
Gonzalo Sapisochin, Tommy Ivanics, Julie Heimbach
Summary: Cholangiocarcinoma is the second-most common primary liver malignancy. Liver transplantation can be considered for intrahepatic and extrahepatic cholangiocarcinoma in select patients based on disease stage and patient characteristics.
Article
Oncology
Salvatore Gruttadauria, Floriana Barbera, Duilio Pagano, Rosa Liotta, Roberto Miraglia, Marco Barbara, Maria Grazia Bavetta, Calogero Camma, Ioannis Petridis, Daniele Di Carlo, Pier Giulio Conaldi, Fabrizio Di Francesco
Summary: Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive liver tumor, with increasing incidence and mortality rates even after radical resection. Recent attention has focused on the disease, supporting liver transplantation as a viable treatment option. Genetic mutations activating signaling pathways have been linked to iCCA tumorigenesis, with a strong association found between Notch pathway mutations and tumor size. Efforts in molecular analysis may improve diagnostic capabilities and treatment protocols for better long-term survival in iCCA and HCC-iCCA patients.
Article
Surgery
Ranish K. Patel, Flavio G. Rocha
Summary: Only a few patients with intrahepatic cholangiocarcinoma can undergo curative resection, even if the disease is limited to the liver. Non-surgical, liver-directed therapies have become primary and complementary treatments due to high recurrence rates, limited surgical candidacy, and liver as a predominant site of relapse. The selection criteria for liver-directed therapies are based on tumor characteristics, liver function, and referral to specialists.
Article
Oncology
Ryusei Matsuyama, Ryutaro Mori, Yohei Ota, Yuki Homma, Yasuhiro Yabusita, Seigo Hiratani, Takashi Murakami, Yu Sawada, Kentaro Miyake, Yasuhiro Shimizu, Takafumi Kumamoto, Itaru Endo
Summary: Gemcitabine/S-1 combination neoadjuvant chemotherapy shows promising efficacy and tolerability in the treatment of perihilar cholangiocarcinoma.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Samuel J. Keltner, Christopher Hallemeier, Kyle Wang, Randa Tao, Shimul Shah, Julie Heimbach, Jordan R. Kharofa
Summary: The use of neoadjuvant radiation therapy for patients with unresectable hilar cholangiocarcinoma before liver transplantation varies greatly. Different radiation doses and fractionation schemes are utilized, with cumulative doses ranging from 40 to 110 Gy (EQD2). Further studies are needed to evaluate the efficacy and toxicity of these different approaches and provide better guidance for best practices.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2023)
Review
Oncology
Francesco Giovinazzo, Marco Maria Pascale, Francesca Cardella, Matteo Picarelli, Serena Molica, Francesca Zotta, Annamaria Martullo, George Clarke, Francesco Frongillo, Antonio Grieco, Salvatore Agnes
Summary: Cholangiocarcinoma (CCA) is a type of malignant tumor arising from the epithelial cells of the biliary tree. Liver transplantation (LT) can be an effective alternative treatment when resective surgery is not feasible, with overall survival rates of 91% at 1 year and 81% at 3 years. However, the scarcity of available organs limits the preferential use of LT in treating CCA, and the management of jaundice and cholangitis remains challenging.
Review
Gastroenterology & Hepatology
Patrick Twohig, Thoetchai Bee Peeraphatdit, Sandeep Mukherjee
Summary: Cholangiocarcinoma is the second most common liver cancer with a relatively short median survival without treatment. Surgical resection is the main treatment method, but a large percentage of tumors are inoperable. However, improvements in patient selection criteria and neoadjuvant treatment protocols have shown promise in improving outcomes for inoperable patients.
WORLD JOURNAL OF GASTROINTESTINAL SURGERY
(2022)
Article
Surgery
Robert R. McMillan, Milind Javle, Sudha Kodali, Ashish Saharia, Constance Mobley, Kirk Heyne, Mark J. Hobeika, Keri E. Lunsford, David W. Victor, Akshay Shetty, Robert S. McFadden, Maen Abdelrahim, Ahmed Kaseb, Mukul Divatia, Nam Yu, Joy Nolte Fong, Linda W. Moore, Duc T. Nguyen, Edward A. Graviss, A. Osama Gaber, Jean-Nicolas Vauthey, R. Mark Ghobrial
Summary: Intrahepatic cholangiocarcinoma (iCCA) has traditionally been considered a contraindication for liver transplantation (LT), but recent studies have shown positive outcomes for LT after neoadjuvant therapy. A center developed a protocol for neoadjuvant therapy and LT for locally advanced, unresectable iCCA patients in 2010. Patients who underwent LT had a high overall survival rate at 1, 3, and 5 years, with a higher than expected proportion of patients with genetic alterations in fibroblast growth factor receptor (FGFR) and DNA damage repair pathways. Further research is needed to determine criteria for LT in iCCA and factors predicting survival.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
